| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/01/2025 | 16:30 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 07/01/2025 | 15:15 | GlobeNewswire Inc. | Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 07/01/2025 | 00:02 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 06/01/2025 | 14:30 | GlobeNewswire Inc. | Recursion to Present at 43rd Annual JP Morgan Healthcare Conference | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 20/12/2024 | 22:05 | GlobeNewswire Inc. | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 17/12/2024 | 23:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 17/12/2024 | 23:05 | Edgar (US Regulatory) | Form 424B7 - Prospectus [Rule 424(b)(7)] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 10/12/2024 | 00:00 | GlobeNewswire Inc. | Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/12/2024 | 14:30 | GlobeNewswire Inc. | Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/12/2024 | 01:02 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 27/11/2024 | 22:09 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 20/11/2024 | 13:11 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 20/11/2024 | 13:00 | GlobeNewswire Inc. | Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 13/11/2024 | 15:08 | GlobeNewswire Inc. | Recursion and Exscientia Shareholders Approve the Proposed Combination | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 12/11/2024 | 22:54 | GlobeNewswire Inc. | Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/11/2024 | 20:17 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 06/11/2024 | 22:18 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 06/11/2024 | 22:15 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 06/11/2024 | 12:12 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 30/10/2024 | 13:22 | GlobeNewswire Inc. | Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 22/10/2024 | 14:00 | GlobeNewswire Inc. | Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 10/10/2024 | 12:00 | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 02/10/2024 | 14:00 | GlobeNewswire Inc. | Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 17/09/2024 | 12:03 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to merger or acquisition | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/09/2024 | 14:00 | GlobeNewswire Inc. | Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 09/08/2024 | 11:44 | IH Market News | TSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and More | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 20:41 | GlobeNewswire Inc. | CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 13:39 | GlobeNewswire Inc. | Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 13:30 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 07:32 | GlobeNewswire Inc. | Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |